Brief: Century Therapeutics Receives Study May Proceed Notification From FDA For CNTY-101 To Overcome Three Major Pathways Of Host Versus Graft Rejection

Century Therapeutics

25/08/2022 12:50

Aug 25 (Reuters) - Century Therapeutics Inc  IPSC.O :
    * CENTURY THERAPEUTICS RECEIVES STUDY MAY PROCEED
NOTIFICATION
FROM FDA FOR CNTY-101, THE FIRST ALLOGENEIC CELL THERAPY PRODUCT
CANDIDATE ENGINEERED TO OVERCOME THREE MAJOR PATHWAYS OF HOST
VERSUS GRAFT REJECTION
    * CENTURY THERAPEUTICS - INVESTIGATIONAL NEW DRUG
APPLICATION FOR
CNTY-101, CLEARED BY FDA
    * CENTURY THERAPEUTICS - PHASE 1 ELIPSE-1 TRIAL EVALUATING
CNTY-101 IN RELAPSED/REFRACTORY CD19 POSITIVE B-CELL
MALIGNANCIES ANTICIPATED TO BEGIN IN 2H22

Source text for Eikon:  ID:nGNX8jHfMY 
Further company coverage:  IPSC.O 

 ((Reuters.Briefs@thomsonreuters.com;))